Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia

Pediatric Blood and Cancer

Volumn 45, Issue 2, 2005, Pages 170-175

  Jeng, Michael R ^c   Naidu, Paula E ^a   Rieman, Martha D ^a   Rodriguez Galindo, Carlos ^a,b   Nottage, Kerri A ^a   Thornton, Donyell T ^a   Li, Chin Shang ^a   Wiang, Winfred C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aplastic anemia; Cytokines; GM CSF; Immune suppression

Indexed keywords

CYCLOSPORIN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROGNOSIS; RETICULOCYTE COUNT; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; TENNESSEE; TREATMENT OUTCOME;

EID: 22244476435     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20278     Document Type: Article

References (37)

1. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999;93:2191-2195.
2. Rosenfeld S, Follmann D, Nunez O, et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: Association between hematologic response and long-term outcome. JAMA 2003;289: 1130-1135.
3. Torres HA, Bodey GP, Rolston KV, et al. Infections in patients with aplastic anemia: Experience at a tertiary care cancer center. Cancer 2003;98:86-93.
4. Martinez-Jaramillo G, Gomez-Morales E, Mayani H. Effect of recombinant human granulocyte macrophage-colony stimulating factor in long-term marrow cultures from patients with aplastic anemia. Am J Hematol 1999;61:107-114.
5. Ganser A, Lindemann A, Seipelt G, et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood 1990;76:1287-1292.
6. Geissler K, Valent P, Mayer P, et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates-synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood 1990; 75:2305-2310.
7. Emerson SG, Yang YC, Clark SC, et al. Human recombinant granulocyte-macrophage colony stimulating factor and interleukin 3 have overlapping but distinct hematopoietic activities. J Clin Invest 1988;82:1282-1287.
8. Guinan EC, Sieff CA, Oette DH, et al. A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood 1990;76:1077-1082.
9. Antin JH, Smith BR, Holmes W, et al. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Inst Mitt 1988;83: 149-153.
10. Falk S, Seipelt G, Ganser A, et al. Bone marrow findings after treatment with recombinant human interleukin-3. Am J Clin Pathol 1991;95:355-362.
11. Nachbaur D, Gratwohl A, Herold M, et al. Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemia. Ann Hematol 1993;66:71-75.
12. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931-1934.
13. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002;119:1075-1082.
14. Locasciulli A, Arcese W, Locatelli F, et al. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group. Lancet 2001; 357:43-44.
15. Meidlinger P, Knobl P, Jager U, et al. Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: Tolerability, efficacy, and changes in the progenitor cell compartment. Ann Hematol 1999; 78:299-304.
16. Kojima S, Fukuda M, Miyajima Y, et al. Cyclosporine and recombinant granulocyte colony-stimulating factor in severe aplastic anemia. N Engl J Med 1990;323:920-921.
17. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049-2054.
18. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood 1995;85:1348-1353.
19. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989;321: 1449-1459.
20. Guinan EC, Lee YS, Lopez KD, et al. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993;81:1691-1698.
21. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
22. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-1778.
23. Champlin RE, Nimer SD, Ireland P, et al. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. Blood 1989;73:694-699.
24. Hord JD, Gay JC, Whitlock JA, et al. Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia. J Pediatr Hematol Oncol 1995;17:140-144.
25. Lopez KD, Guinan EC. GM-CSF clinical trials: Pediatric aplastic anemia and Fanconi's anemia. Pediatr Nuts 1995;21:345-349.
26. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976;48:63-70.
27. Hord J, Wang W, Rogers ZR, et al. Immunosuppression and GM-CSF or PIXY321 are Effective in The Treatment of Children with Acquired Severe Aplastic Anemia. Blood 1998;92;157a.
28. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001;86:862-870.
29. D'Andrea AD, Dahl N, Guinan EC, et al. Marrow failure. Hematology (Am Soc Hematol Educ Program) 2002; 58-72.
30. Shao W, Tian D, Liu C, et al. Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol 2000; 71:350-352.
31. Szklo M, Sensenbrenner L, Markowitz J, et al. Incidence of aplastic anemia in metropolitan Baltimore: A population-based study. Blood 1985;66:115-119.
32. Fullerton HJ, Wu YW, Zhao S, et al. Risk of stroke in children: Ethnic and gender disparities. Neurology 2003;61:189-194.
33. Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004;100:2533-2542.
34. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4:68.
35. Easaw SJ, Lake DE, Beer M, et al. Graft-versus-host disease. Possible higher risk for African-American patients. Cancer 1996; 78:1492-1497.
36. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial. Lancet 2000;356: 1554-1559.
37. Tisdale JF, Dunn DE, Maciejewski J. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. Semin Hematol 2000;37:102-109.